KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Sarepta Therapeutics (SRPT) over the last 8 years, with Q2 2025 value amounting to $106.6 million.

  • Sarepta Therapeutics' Shares Outstanding (Diluted Average) rose 754.36% to $106.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was $106.6 million, marking a year-over-year increase of 754.36%. This contributed to the annual value of $129.6 million for FY2011, which is N/A changed from last year.
  • According to the latest figures from Q2 2025, Sarepta Therapeutics' Shares Outstanding (Diluted Average) is $106.6 million, which was up 754.36% from $100.4 million recorded in Q3 2024.
  • Over the past 5 years, Sarepta Therapeutics' Shares Outstanding (Diluted Average) peaked at $106.6 million during Q2 2025, and registered a low of $88.7 million during Q2 2023.
  • Over the past 3 years, Sarepta Therapeutics' median Shares Outstanding (Diluted Average) value was $99.1 million (recorded in 2024), while the average stood at $96.8 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Shares Outstanding (Diluted Average) surged by 1300.39% in 2024, and later surged by 754.36% in 2025.
  • Quarter analysis of 3 years shows Sarepta Therapeutics' Shares Outstanding (Diluted Average) stood at $88.9 million in 2023, then grew by 13.0% to $100.4 million in 2024, then increased by 6.15% to $106.6 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $106.6 million for Q2 2025, versus $100.4 million for Q3 2024 and $99.1 million for Q2 2024.